FDA Adverse Event Injury Summary report: N

ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT PROXIMAL BODY

MDR report key: 8733135 · Received June 25, 2019

Report

Report Number
9680654-2019-00023
Event Type
Injury
Date Received
June 25, 2019
Date of Event
August 23, 2018
Report Date
August 13, 2019
Manufacturer
WILLIAM A. COOK AUSTRALIA, PTY LTD
Product Code
MIH
UDI-DI
10827002381664
PMA / PMN Number
P020018
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

THE DEVICE WAS NOT RETURNED FOR EVALUATION. WORK ORDER (B)(4) WAS REVIEWED AND APPEARS COMPLETE AND CORRECT. THREE ATTEMPTS WERE MADE TO OBTAIN ADDITIONAL INFORMATION AND MEDICAL IMAGING REGARDING THIS CASE. HOWEVER, NO INFORMATION HAS BEEN RECEIVED. THE DEVICE IFU STATES: "THE LONG-TERM PERFORMANCE AND SAFETY OF ENDOVASCULAR GRAFTS HAS NOT YET BEEN ESTABLISHED. AS A RESULT, LIFE-LONG, REGULAR FOLLOW-UP MUST BE UNDERTAKEN IN ALL PATIENTS TO ASSESS THE ONGOING PERFORMANCE OF THE ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT. PATIENTS WITH SPECIFIC CLINICAL FINDINGS (E.G., ENDOLEAKS, ENLARGING ANEURYSMS OR CHANGES IN THE STRUCTURE OR POSITION OF THE ENDOVASCULAR GRAFT) SHOULD RECEIVE ENHANCED FOLLOW-UP." "INACCURATE PLACEMENT AND/OR INCOMPLETE SEALING OF THE ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT WITHIN THE VESSEL MAY RESULT IN INCREASED RISK OF ENDOLEAK, MIGRATION OR INADVERTENT OCCLUSION OF THE RENAL OR INTERNAL ILIAC ARTERIES. RENAL ARTERY PATENCY MUST BE MAINTAINED TO PREVENT/REDUCE THE RISK OF RENAL FAILURE AND SUBSEQUENT COMPLICATIONS." "UNLESS MEDICALLY INDICATED, DO NOT DEPLOY THE ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT IN A LOCATION THAT WILL OCCLUDE ARTERIES NECESSARY TO SUPPLY BLOOD FLOW TO ORGANS OR EXTREMITIES. DO NOT COVER SIGNIFICANT RENAL OR MESENTERIC ARTERIES WITH THE ENDOPROSTHESIS. VESSEL OCCLUSION MAY OCCUR. CLINICAL STUDIES HAVE IDENTIFIED THAT WITH USE OF THE ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT THERE IS A RISK OF RENAL IMPAIRMENT/LOSS (WHICH COULD LEAD TO A NEED FOR DIALYSIS). CLINICAL STUDIES HAVE SHOWN THAT THIS RISK IS REDUCED WHEN THE RENAL ARTERIES ARE STENTED AS PART OF THE PROCEDURE TO IMPLANT A ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT. STENTING OF THE RENAL ARTERIES IS THEREFORE STRONGLY RECOMMENDED WITH USE OF THE ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT TO REDUCE THE RISK OF RENAL IMPAIRMENT/LOSS." BASED ON THE INFORMATION PROVIDED, THERE IS NO EVIDENCE THAT A DEVICE NON-CONFORMANCE OR DEFICIENCY CONTRIBUTED TO THE COMPLAINT. IT IS POSSIBLE THAT ONE OR MORE OF THE FOLLOWING FACTOR CONTRIBUTED TO THE COMPLAINT: GRAFT IS PRONE TO THROMBUS FORMATION, PATIENT FACTORS, PROCEDURAL FACTORS.

Description of Event or Problem · 0

4 DEVICES WERE IMPLANTED ON (B)(6) 2018. THE PROCEDURE INFORMATION STATES THAT THE LEFT RENAL ARTERY COULD NOT BE CANNULATED SO A CHIMNEY GRAFT WAS IMPLANTED TO MAINTAIN BLOOD SUPPLY TO THE LEFT RENAL ARTERY. ADDITIONALLY, THE INFORMATION INDICATES THE FENESTRATED GRAFT WAS DEPLOYED IN THE INTENDED LOCATION, NO TYPE I OR III ENDOLEAKS, NO DEVICE INTEGRITY ISSUES, AND NO CONVERSION TO OPEN REPAIR.

Description of Event or Problem · 1

4 DEVICES WERE IMPLANTED ON (B)(6) 2018. THE PROCEDURE INFORMATION STATES THAT THE LEFT RENAL ARTERY COULD NOT BE CANNULATED SO A CHIMNEY GRAFT WAS IMPLANTED TO MAINTAIN BLOOD SUPPLY TO THE LEFT RENAL ARTERY. ADDITIONALLY, THE INFORMATION INDICATES THE FENESTRATED GRAFT WAS DEPLOYED IN THE INTENDED LOCATION, NO TYPE I OR III ENDOLEAKS, NO DEVICE INTEGRITY ISSUES, AND NO CONVERSION TO OPEN REPAIR.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
526522 ZENITH FENESTRATED AAA ENDOVASCULAR GRAFT PROXIMAL BODY MIH SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT MIH WILLIAM A. COOK AUSTRALIA, PTY LTD AC1019926 10827002381664

Patients

Seq Age Sex Outcome Treatment
1 80 YR Required Intervention ZFEN-D-12-45-76 TFLE-12-73-ZT TFLE-18-73-ZT| ZFEN-D-12-45-76 TFLE-12-73-ZT TFLE-18-73-ZT| ZFEN-D-12-45-76 TFLE-12-73-ZT TFLE-18-73-ZT